Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Summary

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metastatic Malignant Solid Neoplasm
• Metastatic Melanoma
• Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
• Pathologic Stage IV Cutaneous Melanoma AJCC v8
• Recurrent Malignant Solid Neoplasm
• Refractory Malignant Solid Neoplasm
• Uveal Melanoma
• Acral Melanoma
• Neuroendocrine Tumors
• Paraganglioma
• Pheochromocytoma
• Adrenocortical Carcinoma
• Pancreatic Neuroendocrine Tumor
• Thyroid Cancer
• Breast Cancer
• Lung Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Anusha Kalbasi

Last updated on ClinicalTrials.gov

March 17, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites